Misplaced Pages

Fosdesdenosine sipalabenamide: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyContent deleted Content addedVisualWikitext
Revision as of 13:15, 22 January 2025 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,946 edits created drug stubTag: nowiki added  Latest revision as of 18:42, 22 January 2025 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,946 edits + cite 
Line 109: Line 109:
}} }}


'''Fosdesdenosine sipalabenamide''' is an ] that is being evaluated for the treatment of advanced solid tumors and ].<ref name = "PatSnap">{{cite web | title = Fosdesdenosine sipalabenamide | url = https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/ab788813c70a4b3db1c949c3cf814856 | work = PatSnap }}</ref> This compound is a ] derivative of ] (3'-deoxyadenosine), an adenosine analog originally isolated from the fungus '']''.<ref name = "PubChem">{{cite web | title = Fosdesdenosine Sipalabenamide| url = https://pubchem.ncbi.nlm.nih.gov/compound/166177279 | work = PubChem | publisher = U.S. National Library of Medicine }}</ref> As a nucleoside analog with potential antineoplastic properties, Fosdesdenosine sipalabenamide is designed to inhibit ] and act as an RNA inhibitor.<ref name = "PatSnap" /> The drug is being developed by NuCana Plc.<ref name = "PatSnap" /> '''Fosdesdenosine sipalabenamide''' is an ] that is being evaluated for the treatment of advanced solid tumors and ].<ref name = "PatSnap">{{cite web | title = Fosdesdenosine sipalabenamide | url = https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/ab788813c70a4b3db1c949c3cf814856 | work = PatSnap }}</ref> This compound is a ] derivative of ] (3'-deoxyadenosine), an adenosine analog originally isolated from the fungus '']''.<ref name = "PubChem">{{cite web | title = Fosdesdenosine Sipalabenamide| url = https://pubchem.ncbi.nlm.nih.gov/compound/166177279 | work = PubChem | publisher = U.S. National Library of Medicine }}</ref><ref name="Serpi_2022">{{cite journal | vauthors = Serpi M, Ferrari V, McGuigan C, Ghazaly E, Pepper C | title = Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent | journal = Journal of Medicinal Chemistry | volume = 65 | issue = 23 | pages = 15789–15804 | date = December 2022 | pmid = 36417756 | pmc = 9743095 | doi = 10.1021/acs.jmedchem.2c01348 }}</ref> As a nucleoside analog with potential antineoplastic properties, Fosdesdenosine sipalabenamide is designed to inhibit ] and act as an RNA inhibitor.<ref name = "PatSnap" /> The drug is being developed by NuCana Plc.<ref name = "PatSnap" />


== References == == References ==

Latest revision as of 18:42, 22 January 2025

Pharmaceutical compound
Fosdesdenosine sipalabenamide
Clinical data
Other namesNUC-7738
Identifiers
IUPAC name
  • benzyl (2S)-2-methoxy-phenoxyphosphoryl]amino]propanoate
CAS Number
PubChem CID
DrugBank
UNII
ChEMBL
Chemical and physical data
FormulaC26H29N6O7P
Molar mass568.527 g·mol
3D model (JSmol)
SMILES
  • C(C(=O)OCC1=CC=CC=C1)NP(=O)(OC2C((O2)N3C=NC4=C(N=CN=C43)N)O)OC5=CC=CC=C5
InChI
  • InChI=InChI=1S/C26H29N6O7P/c1-17(26(34)36-13-18-8-4-2-5-9-18)31-40(35,39-19-10-6-3-7-11-19)37-14-20-12-21(33)25(38-20)32-16-30-22-23(27)28-15-29-24(22)32/h2-11,15-17,20-21,25,33H,12-14H2,1H3,(H,31,35)(H2,27,28,29)/t17-,20-,21+,25+,40?/m0/s1
  • Key:UDLWWGQHMQIYCV-LKKHFEEPSA-N

Fosdesdenosine sipalabenamide is an investigational new drug that is being evaluated for the treatment of advanced solid tumors and lymphoma. This compound is a phosphoramidate derivative of cordycepin (3'-deoxyadenosine), an adenosine analog originally isolated from the fungus Cordyceps. As a nucleoside analog with potential antineoplastic properties, Fosdesdenosine sipalabenamide is designed to inhibit RNA synthesis and act as an RNA inhibitor. The drug is being developed by NuCana Plc.

References

  1. ^ "Fosdesdenosine sipalabenamide". PatSnap.
  2. "Fosdesdenosine Sipalabenamide". PubChem. U.S. National Library of Medicine.
  3. Serpi M, Ferrari V, McGuigan C, Ghazaly E, Pepper C (December 2022). "Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent". Journal of Medicinal Chemistry. 65 (23): 15789–15804. doi:10.1021/acs.jmedchem.2c01348. PMC 9743095. PMID 36417756.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Fosdesdenosine sipalabenamide: Difference between revisions Add topic